The Effects of Desmopressin and 6% Hydroxyethyl Starch on Factor VIII
| Autor: | Mark L. Pinosky, Scott Reeves, J M Conroy, John Lazarchick, Richard L. Fishman |
|---|---|
| Rok vydání: | 1996 |
| Předmět: |
Adult
Adolescent medicine.medical_treatment Blood Loss Surgical Plasma Substitutes Hydroxyethyl starch Sodium Chloride Renal Agents Hydroxyethyl Starch Derivatives Blood loss Double-Blind Method Factor viii c Coagulopathy Medicine Humans Deamino Arginine Vasopressin Desmopressin Saline Blood Coagulation Aged Chemotherapy Factor VIII Intraoperative Care business.industry Platelet Count Fibrinogen Middle Aged medicine.disease Anesthesiology and Pain Medicine Elective Surgical Procedures Anesthesia Fluid Therapy Partial Thromboplastin Time business Perfusion medicine.drug |
| Zdroj: | Anesthesia & Analgesia. 83:804-807 |
| ISSN: | 0003-2999 |
| DOI: | 10.1213/00000539-199610000-00026 |
| Popis: | In moderate doses of 20 mL/kg (1.2 g/kg), hydroxyethyl starch (HES) 6% decreases factor VIII:C activity. Desmopressin (DDAVP) increases circulating levels of factor VIII:C by stimulating the release of factor VIII:C from peripheral storage sites. The objective of this study was to monitor the changes in factor VIII:C associated with sequential HES and DDAVP administration. Thirty patients undergoing surgical procedures with a predicted blood loss of less than 750 mL were enrolled. After induction of anesthesia, HES was administered, 20 mL/kg, to a maximum of 1500 mL, at a rate to meet intraoperative fluid requirements. Patients then randomly received either a 10-mL solution containing 0.3 micro gram/kg of DDAVP (Group 1) or 10 mL of normal saline (Group 2). After HES administration, factor VIII:C levels decreased significantly, to 69% of baseline, in both groups. After study drug administration, factor VIII:C in Group 1 increased significantly to 135% of baseline at 30 min and 115% of baseline at 60 min while in Group 2 average factor VIII:C levels remained below baseline at 30 and 60 min. DDAVP produced an increase in factor VIII:C activity despite HES administration and should be considered a treatment option for the mild coagulopathy infrequently associated with HES administration. (Anesth Analg 1996;83:804-7) |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|